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AbstrAct
Genetic information is encoded not only by the linear 
sequence of DNA, but also by epigenetic modifica-
tions of chromatin structure that include DNA methy-
lation and covalent modifications of the proteins that 
bind DNA. These “epigenetic marks” alter the struc-
ture of chromatin to influence gene expression. 
Methylation occurs naturally on cytosine bases at CpG 
sequences and is involved in controlling the correct 
expression of genes. DNA methylation is usually asso-
ciated with triggering histone deacetylation, chromatin 
condensation, and gene silencing. Differentially meth-
ylated cytosines give rise to distinct patterns specific 
for each tissue type and disease state. Such methyla-
tion-variable positions (MVPs) are not uniformly dis-
tributed throughout our genome, but are concentrated 
among genes that regulate transcription, growth, 
metabolism, differentiation, and oncogenesis. Altera-
tions in MVP methylation status create epigenetic 
patterns that appear to regulate gene expression pro-
files during cell differentiation, growth, and develop-
ment, as well as in cancer. Environmental stressors 
including toxins, as well as microbial and viral expo-
sures, can change epigenetic patterns and thereby 
effect changes in gene activation and cell phenotype. 
Since DNA methylation is often retained following 
cell division, altered MVP patterns in tissues can accu-
mulate over time and can lead to persistent alterations 
in steady-state cellular metabolism, responses to stim-
uli, or the retention of an abnormal phenotype, reflect-
ing a molecular consequence of gene-environment 
interaction. Hence, DNA epigenetics constitutes the 
main and previously missing link among genetics, 
disease, and the environment. The challenge in oral 
biology will be to understand the mechanisms that 
modify MVPs in oral tissues and to identify those 
epigenetic patterns that modify disease pathogenesis 
or responses to therapy.
Key words: epigenetics, DNA methylation, 
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epigenetics: connecting 
environment and Genotype to 
Phenotype and disease
INtrodUctIoN
Four years after the unveiling of the complete sequence of the human genome in 2003, “Human Genetic Variation” was recognized by the journal Science 
as the “breakthrough of the year” (Kennedy, 2007). This report emphasized the 
number of studies in that year that led to a new view of human genetic diversity, 
with appreciation of the extent to which our genomic sequences differ from per-
son to person, and the implications of these variations for potentially decipher-
ing the complexity of the biological systems in the human body. Undoubtedly, 
variations in the linear sequence of the genetic code, like single nucleotide poly-
morphisms (SNPs), may play a key role in explaining inter-individual differ-
ences in structure and function, as well as insight into disease susceptibility and 
resistance. However, the function of our genome is also dependent upon epige-
netic mechanisms—which are by definition “beyond the genome”, and include 
alterations of chromatin structure, involving covalent modification of the central 
DNA molecule itself, as well as the complex macromolecules that form chro-
matin. The rapidly evolving field of epigenetics is contributing to our under-
standing of gene-environment interactions, as epigenetic mechanisms exert an 
additional layer of transcriptional control that regulates gene expression.
HIstorIcAL PersPectIVe
Prior to the middle of the twentieth century, before DNA was given a special 
status in biology, the developmental biologist and evolutionist Conrad H. 
Waddington (1905-1975) emphasized that genetics and developmental biol-
ogy were related (Pennisi, 2001), hypothesizing that patterns of gene expres-
sion, turning genes on and off, and not the genes themselves, define each cell 
type, thus linking genes and gene action to development. To denote the 
dynamic actions leading from the genotype to the phenotype, Waddington 
coined the term ‘epigenetics’ from the Greek word epigenesis, referring to 
embryology and genetics as “a gradual coming into being of newly formed 
organs and tissues out of an initially undifferentiated mass”. In this way, 
Waddington indicated that an epigenetic landscape underlies each developing 
organism, referring to the existence of a complex network in which genetic 
interactions, the feedback and “feedforward” relationships among DNA, pro-
teins, and other internal and external biochemical compounds are highly 
intermingled (Van de Vijver et al., 2002). In 1975, two papers were published 
(Holliday and Pugh, 1975; Riggs, 1975) outlining a molecular model for the 
switching of gene activities, and also the heritability of gene activity or inac-
tivity. This model was based on the enzymatic methylation of cytosine in 
DNA. The suggestion was that DNA methylation could have strong effects on 
gene expression, and changes in DNA methylation may therefore explain the 
switching on and off of genes during development, and that the pattern of 
methylation could be heritable, persisting through cell divisions. That is, dur-
ing DNA replication, the methylation patterns in cytosine bases would also be 
conserved during strand duplication. More recently, the scope of epigenetics 
crItIcAL reVIews IN orAL bIoLoGy & MedIcINe
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extends to heritable modifications 
of genes, leading to alteration in 
the expression of specific DNA 
sequences that vary among differ-
ent tissues within the same orga-
nism and cannot be explained by 
changes in DNA sequence.
Epigenetics, as the term sug-
gests, can be seen as a major turn 
away from molecular biology’s 
Central Dogma, recognizing that 
there are epigenetic inheritance 
systems through which non- 
sequence-dependent DNA varia-
tions can be transmitted in cell, 
tissue, and organismal lineages. 
Thus, current epigenetics not only 
offers new insights into gene regu-
lation and heredity, but it also pro-
foundly challenges the way we 
think about evolution, genetics, 
and development. Most interest-
ingly, it suggests testable mecha-
nisms whereby environmental 
factors (ranging from stress to 
infection) can influence genetic 
expression. Furthermore, these 
potential epigenetic modifications 
can occur throughout the lifetime 
of the organism, beginning as early 
as the intra-uterine environment, 
and can accumulate in tissues and 
cells over time to modify gene 
expression patterns and cellular 
phenotypes.
ePIGeNoMe ANd dNA MetHyLAtIoN
The most-studied epigenetic modification of DNA in mam-
mals is methylation of cytosine in CpG dinucleotides (Bird, 
2002). The other main group of epigenetic modifications 
includes post-translational modification of histones, princi-
pally changes in phosphorylation, acetylation, and ubiquitiny-
lation status. Often, these epigenetic mechanisms are coupled 
and interact to modify chromatin structure and function. DNA 
methylation is a covalent biochemical modification that, in the 
mammalian genome, takes place predominantly at cytosine 
bases that are located 5´ to a guanosine (Fig. 1). CpGs are 
vastly under-represented in the genome, as compared with 
what would be expected by chance (0.23 in the human 
genome). Furthermore, CpG-rich regions are not evenly dis-
tributed throughout the genome, but appear most often among 
the promoter regions and first exons of specific genes (Larsen 
et al., 1992). Within the structure of chromatin, DNA is 
complexed with histone proteins to form octamers around 
which DNA loops to form the nucleosome, the individual 
packaging unit of genomic DNA. The enzymes involved in 
DNA methylation include the DNA methyltransferases 
(DNMTs), which establish and maintain DNA methylation pat-
terns using S-adenosyl methionine (SAM) as the methyl donor. 
When DNA becomes methylated, those methyl groups pro-
trude from the cytosine nucleotides into the major groove of 
the DNA to displace transcription factors that normally bind to 
the DNA (Hark et al., 2000). The exposed methylation sites 
attract methyl-binding proteins, the methyl-CpG-binding 
domain proteins (MBDs), which are involved in ‘reading’ 
methylation marks (Loenen, 2006) to affect chromatin conden-
sation by recruiting histone deacetylases that covalently mod-
ify the tails of histone proteins (Vucic et al., 2008). Histone 
modification results in gene silencing and chromatin compac-
tion (Bird and Wolffe, 1999) (Fig. 2).
It is important that methylation patterns be generally con-
served following DNA replication carrying epigenetic patterns 
to cellular progeny, thereby creating a link or communication 
that conveys the developmental or environmental pressures of 
preceding cellular generations. In 2004, Fazzari and Greally 
pointed out that the methylation of CpG-rich promoters is used 
by mammals to prevent transcriptional initiation and to ensure 
Figure 1. Methylation of DNA occurs at cytosine residues when present as CG dinucleotides. Methylation 
occurs by the addition of a methyl group at the 5’ site of cytosine (depicted as shaded sphere).
402  Barros & Offenbacher J Dent Res 88(5) 2009
the silencing of genes on the inactive X chromosome, imprinted 
genes, and parasitic DNAs. The potential role of DNA methyla-
tion in tissue-specific gene expression has been explored more 
recently, since it was realized that CpG methylation can regulate 
tissue-specific gene expression and can be influenced by exter-
nal stressors, environmental toxins, and aging (Dolinoy et al., 
2007; Hanson and Gluckman, 2008), potentially increasing or 
decreasing the level of transcription, depending on whether 
the methylation inactivates a positive or negative regulatory 
element.
The ontological role of DNA methylation, through transcrip-
tional silencing, contributes to an epigenetic regulation of the 
embryonic and morphogenetic developmental gene expression 
program (Holliday and Pugh, 1975). DNA methylation is also 
recognized as an ancient host defense system designed to protect 
against exogenous parasitic nucleic acid sequence elements or 
deleterious endogenous sequences, which have been evolution-
arily incorporated and retained vestigially within our genome 
(Doerfler, 1991; Yoder et al., 1997). In normal cells, DNA methy-
lation occurs predominantly in repetitive genomic regions, includ-
ing satellite DNA and parasitic elements (such as long interspersed 
transposable elements [LINES], short interspersed transposable 
elements [SINES], and endogenous retroviruses [Yoder et al., 
1997]), offering a mechanism by 
which the environment can stably 
change gene expression. Changes in 
methylation status can also regulate 
microRNA (miRNA) expression, 
which, in turn, modulates post-tran-
scriptional gene expression and plays 
important roles in essential processes, 
such as differentiation, cell growth, 
and cell death (Miska, 2005; Zamore 
and Haley, 2005). The key concept is 
that the epigenome, consisting of 
chromatin and its modifications, func-
tions as an interface between the 
inherited genome and the dynamism 
imposed by the environment, and such 
interaction promotes epigenetic modi-
fications that are specific DNA meth-
ylation patterns, which then result in a 
relatively stable or homeostatic pro-
file of gene expression. This has been 
referred to (Feinberg, 2008) as a meta-
stable condition that represents an epi-
genetic modification, resulting in a 
new cellular or tissue homeostatic 
“set-point” with a new range of gene 
expression patterns that differ from 
those of the original state. Chromatin 
modifications, including CpG methy-
lations, allow for sculpting of the 
epigenome during development, mod-
ified by individual environmental 
exposures, providing absolutely 
unique identity, even for monozygotic 
twins (Fraga et al., 2005).
In a landmark publication, Fraga and colleagues (2005) 
reported, in a large cohort of monozygotic twins, that DNA 
methylation increased over time within different tissues and cell 
types, including oral epithelial, lymphocytic, muscle, and fat. 
Most importantly, tissues from identical twins who were 3 years 
of age displayed low levels of DNA methylation and virtually 
identical gene expression profiles for the different tissues obtained 
from each twin, reflecting the high concordance of gene expres-
sion patterns associated with monozygosity, i.e., identical DNA 
sequences. However, when they compared DNA methylation 
patterns in identical twins at the age of 50, there were higher 
DNA methylation levels in general. The gene expression patterns 
in the twins were significantly different, and those differences 
were mapped to the alterations in DNA methylation status. Thus, 
the authors suggested that the “distinct profiles of DNA methyla-
tion and histone acetylation patterns that among different tissues 
(that) arise during the lifetime of monozygotic twins may con-
tribute to the explanation of some of their phenotypic discor-
dances and underlie their differential frequency/onset of common 
diseases”, dependent upon the cumulative history of external 
exposures (i.e., environmental, nutritional, toxins, and infec-
tious) that reprogram epigenetic status.
Figure 2. The shaded sphere depicts the octameric histone complex, which forms the nucleosome with 
the acetylated tails of histones and the cytosines of the CpG sites in an unmethylated state, shown as 
open white circles. In this conformation, the chromatin is loosely packed and available for the binding 
of transcriptional activating proteins, which, by the action of RNA polymerase II, synthesize mRNA. 
The action of DNA methyl transferase (DNMT) methylates the cytosine residues, depicted as red 
circles, which provide a docking site for the methyl binding domain proteins (MBD), which aggregate 
in conjunction with the action of the histone deacetylase, which cleaves the histone acetyl group. Both 
of these serve to alter the structure of the chromatin by causing a condensation that impedes the access 
of the transcriptional activating proteins and thereby blocks mRNA synthesis. Alternatively, the normal 
active structure of chromatin can become inaccessible for the binding of transcriptional activating pro-
teins by the action of CpG methylation at sites that sterically hinder the binding of activating proteins, 
independent of MBD aggregation.
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IMPrINtING
Diploid organisms carry two copies of every autosomal gene, one 
from each parent. In the great majority of cases, the two copies are 
either repressed or transcribed identically, but this is not the case 
for genes that exhibit the phenomenon of parental imprinting. 
Observations through the centuries have suggested that the genes 
passed on by each parent had somehow been permanently 
marked—or “imprinted”, as it eventually came to be known—so 
that the expression patterns of the maternal and paternal genes 
differ in their progeny. Genomic imprinting in mammals repre-
sents a situation where there is non-equivalence in the expression 
of alleles at certain gene loci, dependent on the parent of origin 
(Reik and Walter, 1998).The expression of either the paternally or 
maternally inherited allele is consistently repressed, resulting in 
mono-allelic expression of a particular gene. Thus, imprinted 
genes show markedly different behavior, depending on their 
parental origin. The same pattern of mono-allelic expression is 
faithfully transmitted to daughter cells following cell division. 
Imprinting is not a phenomenon entirely unique to mammals, 
since it also happens in plants, where most commonly the paternal 
genes are imprinted (Grant-Downton and Dickinson, 2005).
However, it is only since 1991 that researchers have begun to 
isolate a variety of genes whose expression depended upon their 
parents of origin. That year, researchers identified two genes, 
Igf2r [insulin-like growth factor-2 receptor] and H19, that are 
active only when inherited from the mother; a third, called Igf2 
[insulin-like growth factor-2], is turned on only when inherited 
from the father. Those findings raised essential questions on 
how genomes become marked differentially during gametogen-
esis, and how this marking is maintained on the gene throughout 
development, as well as prompting a broader search for other 
imprinted genes (Bartolomei et al., 1991; DeChiara et al., 1991; 
Constancia et al., 1998). DNA methylation appears to be the key 
mechanism by which one copy of a gene is preferentially 
silenced according to parental origin and maintained during cell 
division by 5-cytosine DNA methyltransferase-1 (DNMT1) 
(Okano et al., 1999; Miranda and Jones, 2007). DNMT1 prefer-
entially methylates hemi-methylated CpG sites, thus copying 
established methylation patterns to the newly synthesized DNA 
strands. Reik and Walter (1998) proposed that at least a subset 
of ~ 100 genes of the ~20,000-25,000 genes in the mammalian 
genome are thought to be imprinted, and a list of known 
imprinted genes can be accessed at http://www.geneimprint.
com/site/genes-by-status. Although it has not been demon-
strated, it appears likely that many small RNA sequences that 
arise from non-coding regions, and are also involved in gene 
regulation and metabolism, might be candidates for epigenetic 
marks and possibly demonstrate parent-of-origin imprinting 
properties. This possibility is suggested by the presence of CpG-
rich regions that are occasionally present in non-coding regions, 
including miRNAs. The concept of imprinting is an interesting 
example of interactions between heterologous genomes (mater-
nal and paternal) that seek to establish some sort of mutually 
acceptable state of equilibrium. The role of imprinting in IGF2 
regulation in placental and fetal growth is a fascinating example. 
This insulin-like growth hormone is the major somatic growth 
factor for the fetus, since it enhances placental nutrient exchange 
of glucose for fetal growth, and it serves as a pluripotent tissue 
growth hormone for the fetus. IGF2 impairment restricts fetal 
growth. It is perhaps no surprise that the paternal genome serves 
to enhance IGF-II secretion to stimulate the transfer of nutrients 
from mother to fetus to make the baby as large and healthy as 
possible, whereas the maternal genome seeks to attenuate this 
response by controlling the expression level of the receptor for 
this hormone. Thus, one can appreciate that the epigenetic 
response that mediates IGF2 gene expression strikes a balance 
between competing genetic programs. It now appears that epi-
genetic mechanisms serve to mediate genomic conflict that can 
occur between host and exogenous genomes such as those pro-
vided by viral infections or even the commensal microbiome.
deVeLoPMeNt
Differences in programmed gene expression that result in the 
development of organs, tissues, and cell lineages generally occur 
without changes to the sequence of our DNA (with one or two 
exceptions, e.g., immunoglobulin synthesis), indicating that 
development is, by definition, epigenetic (Reik, 2007). Certain 
cell lineages are dependent upon epigenetic programs that 
sequentially regulate gene expression patterns to direct differen-
tiation, maturation, and function effectively. The helper T-cell 
population of the immune system is an example of this epige-
netic programming (Ansel et al., 2003). During the differentia-
tion of CD4+ T-cells, there is an epigenetic activation of the 
interferon gamma gene (IFNG) and a silencing of the interleukin 
4 (IL4) gene. This results in a progressive polarization of T-cell 
responsiveness as the epigenetic modifications are further modi-
fied by antigenic and cytokine actions via sequential divisions 
within the lineage. Thus, different T-helper cells emerge and 
maintain a polarized phenotype based upon epigenetic modifica-
tions that are retained following cell divisions, but additionally 
polarized by antigenic and environmental cytokines, which add 
to the epigenetic modulation. In mice, naïve T-cells have hyper-
methylated CpG islands within the Il4 locus. Extended demethy-
lation within this region results in Il4 gene activation and is 
coupled to Ifng silencing, leading to a TH2 phenotype commit-
ment. Retention of Il4 methylation and Ifng activation results in 
a TH1 phenotype. Thus, epigenetic memory of the T-cells and the 
lineage modulates immune responses via TH2 (which up-regu-
lates IL4, IL5, and IL13) or TH1 (with enhanced IFN-γ and IL-2) 
cytokine responses (Fields et al., 2002).
During development, imprinting of fetal tissues includes 
the placenta, principally targeting trophoblast cells. Abnormali-
ties in placental imprinting have been recently implicated as a 
cause of preeclampsia (Van Dijk et al., 2005) and fetal growth 
restriction (McMinn et al., 2006). Imprinting patterns have 
been associated with congenital disorders affecting growth and 
neuro development that persist into adulthood, including Prader-
Willi and Angelman syndromes, which are two clinically 
distinct diseases associated with abnormal imprinting on chro-
mosome 15q11-q13. Loss of maternal imprinting is responsible 
for the Angelman syndrome, which is characterized by mental 
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retardation, ataxia, and social disposition. In Prader-Willi syn-
drome, loss of paternal imprinting in the same region is charac-
terized by learning difficulties, hypogonadism, short stature, and 
small hands and feet. Beckwith-Weidemann syndrome, another 
imprinting disorder characterized by macrosomia, hemihyper-
trophy, abdominal wall defects, organomegaly, and susceptibil-
ity to Wilm’s tumor, is the result of loss of imprinting of 
insulin-like growth factor 2 (IGF2) on chromosome 11p15 
(Reik and Maher, 1997; Tycko and Morison, 2002). We recently 
demonstrated, in a pregnant murine model, that infection with 
Campylobacter rectus could induce an alteration in placental 
Igf2 methylation patterns that resulted in reduced insulin-like 
growth factor II mRNA expression with an associated fetal 
growth restriction (Bobetsis et al., 2007). This suggests that 
external stimuli or stressors like infection can modify imprinting 
patterns in utero.
eNVIroNMeNtAL stressors As 
ePIGeNetIc ModIFIers
Alterations in DNA methylation status as a result of environmen-
tal stressors have been documented to begin before birth. For 
example, the methylation of fetal DNA that occurs in utero as a 
result of low dietary levels of folate, methionine, or selenium can 
change epigenetic programming that can persist into adulthood 
(Post et al., 1999; Lund et al., 2004; Zaina et al., 2005). Although 
many epigenetic marks are potentially reversible, the mecha-
nisms for reversal remain to be clearly elucidated, and many 
epigenetic changes appear to persist throughout the cell lineage 
and life of the organism. This provides perhaps an explanation 
for the Barker hypothesis (Barker et al., 2002), which posits that 
intra-uterine exposures can result in fetal programming that per-
sists into adulthood and may contribute to the risk for adult-onset 
diseases such as cardiovascular disease and type 2 diabetes.
Intra-uterine nutrition can determine epigenetic program-
ming of the fetus. For example, methyltetrahydrofolate (folate) 
is a critical methyl donor for S-Adenosyl Methionine (SAM), 
which is used by the enzyme DNA methyltransferase (DNMT) 
to methylate CpG residues selectively during embryonic devel-
opment (Razin and Shemer, 1995; Carlone and Skalnik, 2001; 
Hershko et al., 2003). Maternal folate deficiency during preg-
nancy leads to inadequate levels of SAM, a critical substrate for 
DNMT-dependent methylation (Okano et al., 1999). Folate defi-
ciencies can thereby result in DNA hypomethylation, which can 
contribute to improperly elevated expression of certain genes, as 
well as genetic instability facilitating abnormal chromosomal 
re-arrangements (Zaina et al., 2005). These folate deficiencies 
often result in abnormalities in placental development and func-
tion and alter patterns in fetal DNA methylation that can result 
in growth defects and birth anomalies, including neural tube 
defects (Blom et al., 2006). Thus, gross nutritional deficiencies 
can lead to impairment of normal epigenetic programming, 
resulting in abnormal ontological outcomes.
Such dietary or other exogenous environmental factors also 
appear to modulate chromatin epigenetic marks throughout life. 
For example, hyperhomocysteinemia (a marker for low levels of 
methyl donors) is associated with global hypomethylation and 
has been reported in atherosclerosis models and in humans, 
which supports an emerging view that alterations in global 
methylation patterns are characteristic of early stages of cardio-
vascular disease. In advanced stages of atherosclerosis, smooth-
cell proliferation or monocytic clonal expansion within the 
atheroma may be associated with altered DNA methylation 
patterns (Castro et al., 2006). The first findings linking 
DNA methylation of CpG islands to cardiovascular disease 
identified increased methylation of the CpG region of the estro-
gen receptor-α (ERα) gene seen in coronary atherectomy or 
carotid endarterectomy samples (Post et al. 1999).
It has also been proposed that sensitivity to diet or to envi-
ronmental toxins may vary among individuals, due to pre- 
existing genetic variants that can challenge methyl metabolism 
and predispose individuals to epigenetic changes (Lund and 
Zaina, 2007). Other environmental stimuli that may potentially 
function as epigenetic modifiers are exposures to metals and 
aromatic hydrocarbons (e.g., benzopyrene), found in occupa-
tional chemicals, fossil fuel emissions, contaminated drinking 
water, cigarette smoke, and infection (Risch and Plass, 2008). A 
recent study on the influence of smoking on global DNA methy-
lation indicated that smoking induces generalized alterations in 
DNA methylation across multiple tissues and organ systems, 
also showing an association of the offspring’s DNA methylation 
with paternal DNA methylation that was strongest if both had 
never smoked (p = 0.02) (Hillemacher et al., 2008). The authors 
also found that the association completely vanished if descen-
dants smoked themselves or had ever smoked, suggesting an 
association between smoking behavior and global DNA methy-
lation, which may be of importance for a wide range of diseases. 
Smoking may also be linked to oncogenesis by inducing specific 
epigenetic modifications (Tessema et al., 2008). For example, 
promoter methylation of several tumor suppressor genes has 
frequently been reported in a high percentage (20-100%) of 
human lung cancers (Zochbauer-Muller et al., 2002). Methylation 
of the tumor suppressor p16 gene has been suggested to play a 
critical role in lung cancer survival rate pathogenesis (Kim 
et al., 2001; von Zeidler et al., 2004; Dammann et al., 2005).
ePIGeNetIcs, cANcer, ANd INFLAMMAtIoN
The best-studied epigenetic alteration in cancer is DNA methyla-
tion. During tumorigenesis, methylation is usually decreased 
genome-wide, with selective hypermethylation of CpG sites within 
promoters of tumor-suppressor genes, leading to their silencing 
and subsequent tumor progression (Breivik and Gaudernack, 
1999). This suggests that oncogenesis may also occur through 
epigenetic dysregulation. Feinberg (2007) has recently reviewed 
the epigenetic mechanisms involved with oncogene activation or 
tumor suppressor gene silencing in cancer initiation and progres-
sion, discussing the new idea that epigenetic modifications may 
play a role in cancer predisposition, and that such changes should 
be considered as targets for preventive oncology.
The role of host inflammation on modification of epigenetic 
patterns is still unknown, but the activation of the immune 
response involving potential epigenetic changes has been 
suggested (Adcock and Lee, 2006). Inflammatory signals that 
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activate NF-κB have been shown to alter histone methylation 
patterns and activate gene expression (Ito, 2007). Thus, inflam-
mation has some potential to modify chromatin structure via 
histone structure; however, the role of inflammation in modulat-
ing CpG methylation patterns, which are more likely to be 
conserved following cell replication, remains unclear. Recent 
reports suggest that loss of epigenetic control over this complex 
process contributes to autoimmune disease (Yung and Julius, 
2008). Logically, this may involve abnormal function and matu-
ration in T-cell lineages as a consequence of aberrant epigenetic 
patterns.
Epigenetic mechanisms may also explain, in part, the linkage 
between inflammation and oncogenesis, and the relationship 
between CpG island methylation phenotype in tumors and 
inflammation has been discussed (Shaw et al., 2007). For 
example, gastric inflammation due to bacterial infection with H. 
pylori has been linked to alteration in DNA methylation patterns 
of tumor suppressor genes (Tsuji et al., 2006; Ushijima, 2007). 
H. pylori is an etiologic gastric carcinogen, with about 80% of 
gastric cancers being H. pylori-related (Forman et al., 1991). 
However, the cancer risks are different among H. pylori-infected 
individuals, which probably reflects the diversity of H. pylori 
strains, and differences in host susceptibility or other environ-
mental factors (Uemura et al., 2001). There exists, however, a 
close anatomical relationship in cancerous lesions, whereby H. 
pylori is in direct contact with gastric cells that display altered 
MVP methylation patterns. One specific MVP target in gastric 
cancer appears to be cyclo-oxygenase 2 (COX-2). Low levels of 
gastric secretion of prostaglandin E2 (a product of cyclo-oxyge-
nase 2) and COX-2 suppression have long been known to be 
associated with gastric cancer. Recent studies (Huang et al., 
2006; Perri et al., 2007) have demonstrated that cancerous gas-
tric cells exhibit abnormal PTGS2 (Prostaglandin G/H 
Synthase-2) promoter hyper methylation patterns. Non-cancerous 
regions of the gastric lesion do not demonstrate the presence of 
H. pylori or the abnormal PTGS2 promoter hypermethylation 
and COX-2 suppression. Thus, the evidence supports the con-
cept that the H. pylori infection promotes oncogenesis by epige-
netic modification that includes the PTGS2 promoter.
In 2007, we were the first group to report alteration in DNA 
methylation status of the Igf2 gene in murine placental tissues 
due to maternal infection with the periodontopathogenic bacte-
ria Campylobacter rectus (Bobetsis et al., 2007). By analogy, H. 
pylori and C. rectus are close phylogenetic neighbors that share, 
for example, GroEL protein (HSP60 family) expression, which 
can stimulate IL-6 production (Tanabe et al., 2003). We were 
able to demonstrate, in placentas from growth-restricted fetuses, 
that the hypermethylation found in the promoter region (P0) of 
the Igf2 gene was related to the C. rectus placental exposure in 
pregnant mice. This appears causal, since Igf2 gene function 
involves growth and development. Population studies have 
shown that, among humans, prematurity and impaired fetal 
growth have been associated with adult-onset diabetes and car-
diovascular disease (Barker et al., 2002). If abnormalities in 
IGF2 methylation were to occur in utero among humans, it is 
possible that these epigenetic marks could persist into adulthood 
and may be associated with the observed abnormalities in IGF2 
metabolism in adults with cardiovascular disease and diabetes. 
Thus, the role of infection as an intra-uterine modifier of epige-
netic programming should be considered as a possible link to 
adult disease. This may be particularly relevant in humans, since 
C. rectus exposure of the fetus has been found to be associated 
with preterm delivery (Madianos et al., 2001).
Following the observation and establishment of a connection 
between oral bacteria altering placental DNA methylation, we 
asked the question, Could the oral biofilm epigenetically modify 
the local adjacent periodontal tissues? We have conducted a pilot 
survey using CpG Island Microarray analysis (data not shown) 
comparing genomic-wide MVP methylation status of periodon-
tally diseased gingival tissues with healthy gingival tissue. We 
could preliminarily identify a list of genes that were differentially 
methylated in gingival tissues from individuals with periodontal 
disease, and these results will be forthcoming shortly. Thus, the 
role of bacterial infection and chronic inflammation as a potential 
stimulus for altering local periodontal tissue DNA methylation 
patterns provides a fertile area for further investigation. Furthermore, 
the link between inflammation and oral cancer is well-established, 
and a connection between bacterial infection and inflammation is 
evident. Thus, epigenetic influences may serve as a plausible 
potential mechanism that connects all three pathways and should 
be further explored, especially as it relates to mucosal cancers, 
which emerge in the presence of high microbial burdens.
ePIGeNetIc MArKs IN cArcINoGeNesIs
Epigenetic changes set the stage for alterations in gene expres-
sion and have been identified as important components of 
carcinogenesis. As previously mentioned, global DNA hypo-
methylation is a general feature of genomic DNA derived from 
solid and hematologic tumors as isolated from animal models 
and human tumors (Gaudet et al., 2003; Fraga et al., 2005; Holm 
et al., 2005). Hypomethylation is consistent with the overall 
increased transcriptional activity seen in most tumors. However, 
loss of DNA methylation, which often occurs at sequences which 
are unstable, is likely related to increased tumor frequency due to 
chromosomal instability, and it has been considered as the earli-
est epigenetic change from a normal to a pre-malignant cell. 
However, the expression of certain oncogenes appears to be 
directly activated by hypomethylation, whereas hypermethyla-
tion of tumor suppressor genes can also be seen. Examples of 
promoter DNA hypermethylation and chromatin hypoacetyla-
tion, which result in the silencing of tumor suppressor genes, 
include p16 (also known as cyclin-dependent kinase inhibitor 
2A) and MutL protein homologue 1 (MLH1) (Herman and 
Baylin, 2003; Feinberg and Tycko, 2004).
In a recent review, Choi and Myers (2008) emphasized the 
genetic and epigenetic alterations in the molecular pathogenesis 
of oral squamous cell carcinoma (OSCC), discussing the role of 
oncogenes like Ras oncogene, Cyclin D1, AP-1 complex, and 
tumor suppressor genes like p53, p16, and p21. These investiga-
tors reported aberrant hypermethylation patterns in the promoter 
region of p16 and E-cadherin which influence cell division and 
cell-cell adhesion, respectively. p16 was one of the first genes to 
be found associated with aberrant DNA methylation patterns in 
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head and neck cancer (Reed et al., 1996). p16 inhibits G1 to S 
phase passage by binding cyclin-dependent kinase, preventing 
formation of its complex with cyclin D. Methylation of p16 
promoter has been considered as a predictive marker for malig-
nant transformation, since the methylation depicts uncontrolled 
cell division (Hall et al., 2008). In OSCC, p16 methylation has 
been reported to vary between 31% (Maruya et al., 2004) and 
67% (Kulkarni and Saranath, 2004). E-cadherin plays a role in 
cell-cell adhesion, and, when underexpressed, may affect tumor 
invasion by leading to a greater probability of tumor invasion or 
metastasis. E-cadherin was found silenced by hypermethylation 
in other studies of oral cancer (Hasegawa et al., 2002; Kudo 
et al., 2004; Maruya et al., 2004).
Other genes have also been investigated for aberrant DNA 
methylation in oral squamous cell carcinomas. The epigenetic 
silencing of the MGMT (O6-methylguanine–DNA methyltrans-
ferase) DNA-repair gene which, by promoter methylation, com-
promises DNA repair, has been considered an early event in the 
development of oral cancer and is associated with 25-52% of 
primary oral squamous-cell carcinomas (Viswanathan et al., 
2003; Kulkarni and Saranath, 2004; Maruya et al., 2004). The 
death-associated protein kinase 1(DAPK1) gene, a tumor- 
suppressor gene involved in apoptosis, is also found methylated 
between 7% and 68% in oral cancers (Li, 2002; Ogi et al., 2002; 
Maruya et al., 2004).
It has also been shown that miRNAs, which modulate post-
transcriptional gene expression, can be aberrantly expressed or 
mutated in cancers, suggesting that they may also function as 
oncogenes or tumor suppressor genes. More recently, studies have 
shown that miRNA genes may be regulated also by epigenetic 
mechanisms and have even been identified embedded within CpG 
islands (Lujambio and Esteller, 2007). The promoter of an 
miRNA methylated in normal tissues can be maintained in cancer, 
as in the case of two putative tumor suppressor miRNAs— 
miR-127 and miR-124a—which are transcriptionally inactivated 
by CpG island hypermethylation (Saito et al., 2006; Lujambio 
et al., 2007), whereas in lung cancer, the overexpression of let-
7a-3 seems to be due to DNA hypomethylation (Brueckner et al., 
2007; Weber et al., 2007). In both cases, the functional signifi-
cance is the opposite. miR-127 and miR-124a seem to act as 
tumor suppressors, and so methylation is maintained in cancer, 
while let-7a-3 is thought to act as an oncogene, so its demethyla-
tion would contribute to the tumoral phenotype. Clearly, the role 
of epigenetic influence on miRNA function is a new area of inves-
tigation and represents just one area in which the role of epigenet-
ics and oral disease needs further exploration.
Future research will help us understand, for example, how 
systemic exposures, like smoking, may alter global epigenetic 
patterns to affect the expression of oral conditions such as oral 
cancer or advanced periodontitis. We need to understand how 
the oral microbiome and local biofilm may create an epigenetic 
“footprint” in the adjacent mucosa and periodontal tissues, and 
potentially modify the local inflammatory response and onco-
genic potential. Biofilm-induced epigenetic patterns may influ-
ence local tissue metabolism to alter the microbial ecology and 
alter local healing responses of the periodontal tissues. Recently, 
Park and colleagues (2008) were able to reprogram somatic 
human cells to a pluripotent state, which is in essence a reversal 
of differentiation to a more embryonic state, by inducing the 
ectopic expression of four transcriptional regulatory factors 
(Oct4, Sox2, Klf4, and Myc). This resulted in significant epige-
netic remodeling, which was sufficient to result in cellular 
reprogramming to a pluripotent state. This suggests that epige-
netic reprogramming might prove to be a mechanism to create 
new wound-healing or tissue-regenerative potential, and agents 
which modify epigenetic patterns are a fertile area for new drug 
development strategies. These are just a few important questions 
and opportunities that will await further studies that explore the 
role of epigenetics in oral biology. Thus, epigenetic codes, 
which are just becoming revealed, can help us better understand 
the biological phenotype that arises from the interaction of the 
human genome with the environment in health and in disease.
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